Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo

Figures & data

Figure 1 Inhibitory effect of BIBF 1120 on growth of NPC cell lines.

Notes: Cancer cell proliferation was calculated as a percentage of control cell growth. Each point represents the mean of triplicate values ± SD.
Abbreviations: NPC, nasopharyngeal carcinoma; SD, standard deviation.

Figure 2 Effect of BIBF 1120, DDP, or combination on the growth of HNE-1 xenografts.

Notes: Tumor volume of HNE-1 xenografts. Mean tumor volume is shown. Data points represent a mean from six to nine mice; bars, SD. *P<0.05 versus control.
Abbreviations: SD, standard deviation; DDP, cisplatin.

Figure 3 Effect of BIBF 1120, DDP, or combination on the growth of HNE-1 xenografts.

Notes: Body weight of HNE-1 xenografts. Mean body weight is shown. Data points represent a mean from six to nine mice; bars, SD. *P<0.05 versus control.
Abbreviations: SD, standard deviation; DDP, cisplatin.

Figure 4 VEGF and VEGFR immunostaining within the tumor of HNE-1 NPC xenograft at day 26.

Notes: (A) VEGF, (B) VEGFR1, and (C) VEGFR2. Typical images of strong positive intensities of staining are shown (×200 magnification).
Abbreviations: VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; NPC, nasopharyngeal carcinoma.

Figure 5 CD31 immunostaining for microvessel density within the tumor of HNE-1 NPC xenograft at day 26.

Note: Typical images of control group and BIBF 1120 group are shown (×200 magnification).
Abbreviation: NPC, nasopharyngeal carcinoma.

Table S1 The percentage of inhibition of BIBF 1120 on nasopharyngeal carcinoma cell lines

Cell lines	0.078 µM	0.156 µM	0.3125 µM	0.625 µM	1.25 µM	2.5 µM	5 µM	10 µM
CNE-2	0.022	0.092	0.164	0.239	0.285	0.301	0.461	0.751
HONE-1	0.076	0.092	0.171	0.200	0.236	0.311	0.408	0.713
HNE-1	0.118	0.151	0.181	0.236	0.267	0.362	0.536	0.710